Analyst firms · Chardan Capital Markets · FBRX
Chardan Capital Markets FBRX price target and rating history
Forte Biosciences Inc. (FBRX) · Health Care
Chardan Capital Markets rates Forte Biosciences Inc. (FBRX) Buy with a $3.50 price target, as of its latest action on Sep 20, 2021. It has published 3 rating actions on FBRX since September 2021, including 2 upgrades and 1 downgrade.
- Current rating
- Buy
- Price target
- $3.50
- Median target, all firms
- Too few
- Actions on FBRX
- 3
Chardan Capital Markets price target on FBRX
Every Chardan Capital Markets rating on FBRX
- Sep 20, 2021
- Sep 20, 2021
- Sep 3, 2021
How other firms rate FBRX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Overweight | $74 | Jul 21, 2026 |
| Evercore ISI | Outperform | $65 | Nov 25, 2025 |
Questions about Chardan Capital Markets and FBRX
- What is Chardan Capital Markets's price target for FBRX?
- Chardan Capital Markets's latest stated price target for Forte Biosciences Inc. (FBRX) is $3.50, from its action on Sep 20, 2021.
- What is Chardan Capital Markets's rating on FBRX?
- Chardan Capital Markets rates FBRX Buy, a bullish rating, as of Sep 20, 2021.
- When did Chardan Capital Markets last change its view on FBRX?
- On Sep 20, 2021, Chardan Capital Markets upgrades to Buy from Sell, price target $4 to $3.50.
All Chardan Capital Markets ratingsFBRX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.